Last updated on February 2020

A Phase II Study of the FIL on Elderly Frail Patients With DLBCL

Brief description of study

A phase II study to evaluate the combination of Lenalidomide and Rituximab as front line therapy for the treatment of elderly frail patients evaluated in CGA with Diffuse Large B-cells non-Hodgkin Lymphoma.

Detailed Study Description

This is a prospective, multicenter, single arm, phase II trial in elderly patients ( 70 years) affected by DLBCL defined as frail according to CGA and previously untreated.

The primary endpoint is to evaluate the efficacy of the R2 (Revlimid+Rituximab) combination in first line DLBCL patients not candidate for the standard R-CHOP (or R-CHOP like) treatments due to the frail status.

Clinical Study Identifier: NCT02955823

Find a site near you

Start Over